Sick or Treat: eCancerLessons from the world of neglected disease R&D

Dr Nick ChapmanDirector of Research, Policy Cures

Sydney, 28 October 2015

Comparing global investment in R&D

All health R&D $270bn

Cancer$15bn

Rare cancers$3.0bn? Neglected diseases

$3.2bn

Two ends of the spectrum

Revenue = Price x Volume

Solutions for neglected disease R&D

• Public and philanthropic funding

• Product Development Partnerships

• Other innovative mechanisms

Public and philanthropic funding

Two thirds from top 3 funders:

- US NIH (39%)

- Gates Foundation (16%)

- Pharma industry (12%)

Product Development Partnerships (PDPs)

Product Development Partnerships (PDPs)

PDPs are involved in 40% of all pipeline candidates

… despite managing only 15% of total funding for

neglected disease R&D in 2013

Target Product Profiles – focus on patient needs from the outset (incl. max acceptable price)

Other incentives

• Priority Review Vouchers

• Global Health Innovative Technologies fund

• Global Health Investment Fund

These approaches have helped grow the ND R&D pipeline…

The R&D pipeline for neglected diseases is healthier now than it has ever been

485product candidates in the pipeline

2004 2012 2015

215?

365

485

… but less for the ‘most neglected’ – just as for rarest

Highly concentrated on just three diseases (malaria, TB, and HIV/AIDS)

Malaria Tubercu-losis HIV/AIDS

Kine-toplas-

tids

Diarrhoeal diseases

Helminth infections

Hepatitis C

All other diseases

combined

67%

Access gap

?